D and c to remove polyps: Dilation and curettage (D&C) – Mayo Clinic

13.06.197301.09.2021 by alexxlab

Содержание

Current practice in the removal of benign endometrial polyps: a Dutch survey

Gynecol Surg. 2012; 9(2): 163–168.

,¹,^1,²,³,² and ²

Lotte J. E. W. van Dijk

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

Maria C. Breijer

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

Sebastiaan Veersema

³Department of Obstetrics & Gynecology, St. Antonius Hospital, Nieuwegein, The Netherlands

Ben W. J. Mol

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

Anne Timmermans

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

³Department of Obstetrics & Gynecology, St. Antonius Hospital, Nieuwegein, The Netherlands

Corresponding author.

Received 2011 Aug 15; Accepted 2011 Oct 1.

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

This article has been cited by other articles in PMC.

Abstract

The purpose of this study is to evaluate the current practice of Dutch gynecologists in the removal of benign endometrial polyps and compare these results with the results of a previous study from 2003. In 2009 Dutch gynecologists were surveyed by a mailed questionnaire about polypectomy. Gynecologists answered questions about their individual performance of polypectomy: setting, form of anesthesia, method, and instrument use. The results were compared with the results from the previous survey. The response rate was 70% (585 of 837 gynecologists). Among the respondents, 455 (78%) stated to remove endometrial polyps themselves. Polyps were mostly removed in an inpatient setting (337; 74%) under general or regional anesthesia (247; 54%) and under direct hysteroscopic vision (411; 91%). Gynecologists working in a teaching hospital removed polyps more often in an outpatient setting compared with gynecologists working in a nonteaching hospital [118 (43%) vs. 35 (19%) p < 0.001]. These results are in accordance with the results from 2003. Compared to 2003 there was an increase in the number of gynecologists performing polypectomies with local or no anesthesia [211 (46%) vs. 98 (22%), p < 0.001]. An increase was also noted in the number of gynecologists using direct hysteroscopic vision [411 (91%) vs. 290 (64%), p < 0.001] and 5 Fr electrosurgical instruments [181 (44%) vs. 56 (19%), p < 0.001]. Compared to the situation in 2003, there is an increase in removal under direct hysteroscopic vision, with 5 Fr electrosurgical instruments, using local or no anesthesia. This implies there is progress in outpatient hysteroscopic polypectomy in the Netherlands.

Keywords: Polypectomy, Hysteroscopy, Inpatient, Outpatient

Background

Benign endometrial polyps are frequently associated with abnormal uterine bleeding [1–4]. Endometrial polyps have a low potential for (pre)malignancy. However age and postmenopausal bleeding are factors which are associated with malignancy [3, 5–7]. Most gynecologists (up to 93%) will remove endometrial polyps in patients with abnormal uterine bleeding symptoms [8]. Although case series, cohort studies, and retrospective studies on this subject exist, few studies address this question prospectively in a comparative cohort study or a randomized controlled trial [9, 10]. Removing endometrial polyps is thought to improve symptoms of abnormal uterine bleeding and increase satisfaction rate in women with endometrial polyps [11, 12]. The evidence that justifies the removal of endometrial polyps however is limited.

Traditionally, endometrial polyps were removed by dilatation and curettage (D&C). However, in approximately 57% of the D&C procedures endometrial polyps are not detected and D&C fails to extract endometrial polyps in 60–87% of the cases [13, 14]. Former surveys have demonstrated that D&C for polyp removal has not been completely abandoned: 2% of gynecologists in the UK removed polyps with D&C and 56% removed polyps with D&C following hysteroscopy [8]. In 2003, in the Netherlands, 4% of the gynecologists removed polyps with D&C and 27% used D&C following hysteroscopic localization. The preferred method of Dutch gynecologists is hysteroscopic removal (69%) [15]. Moreover, hysteroscopic polypectomy is the most performed hysteroscopic procedure in the Netherlands [16].

Large prospective cohort studies and randomized controlled trials have demonstrated that outpatient hysteroscopy and polypectomy are feasible, safe, and effective with high patient satisfaction rates [17–23]. Compared to the inpatient setting, patients treated in the outpatient setting recover faster, leading to a decrease in time away from home and work [24]. Nevertheless, our previous study revealed that in 2003, outpatient hysteroscopic polypectomy in the Netherlands was not practiced on a large scale (29% of gynecologists). However, we saw that outpatient hysteroscopic polyp removal was more often practiced in teaching hospitals compared with nonteaching hospitals. We therefore hypothesized that there might be a tendency towards outpatient hysteroscopic polypectomy. To evaluate this hypothesis, we conducted the current survey.

Materials and methods

All practicing gynecologists, holding membership of the Dutch association of obstetrics and gynecology (NVOG), in 2009 were identified from the national database. Gynecologists in training were not included. All gynecologists were approached by mail and received a questionnaire with a cover letter and prepaid return envelope. Different criteria were met to achieve the best response rate: the questionnaire was brief, fitting on one page; was explicit; and had a structured format consisting of three items subdivided in closed questions. To assure a higher response rate, a reminder was sent to the nonresponders after 8 weeks and a second reminder was sent by mail and email after another 12 weeks.

The questionnaire concerned questions about the medical practice of gynecologists, when a benign polyp was suspected following ultrasound or endometrial biopsy. Recipients were asked in what type of hospital they were working: a teaching hospital, with a residency program for gynecology, or a nonteaching hospital. Subsequently, gynecologists were asked to report whether they performed endometrial polypectomy themselves. Only those who did were then requested to report about setting (inpatient, day care, outpatient), form of anesthesia (general, regional, local or none), method of polyp removal (D&C, D&C after hysteroscopic localization or under direct hysteroscopic visualization), and type of hysteroscopic instrument used (5 Fr mechanical instruments, 5 Fr electrosurgical instruments, resectoscope, or morcellator).

Respondents were asked to report whether they performed the different modalities as a standard method, incidentally or never at all. The options that were chosen as a standard were used for further analysis. It was possible to leave questions unanswered or give multiple answers to one question (e.g., general and regional anesthesia as a standard method).

An inpatient setting was considered an operating theater with an anesthesiologist present for general or regional anesthesia and at least one night stay in the hospital. A day care setting was considered an operating theater with an anesthesiologist present, but discharge from the hospital the same day. A “walk-in-walk-out” procedure, without the presence of an anesthesiologist and without hospital admission, was considered an outpatient setting. Since the inpatient setting and day care setting both require hospital admission and use of an operating theater, they were analyzed together as one category. The same was applied to the form of anesthesia: general and regional anesthesia both require an anesthesiologist and were analyzed as one category. Local anesthesia is administered by a gynecologist and was therefore analyzed together with no anesthesia as one category. These categories enabled comparison of the current results with the results from 2003.

Statistical analysis

All data were processed anonymously. The information was collected, and descriptive statistical analyses were performed with SPSS for Windows® Release 15.0 Standard Version (Chicago, IL, USA). Answers given by gynecologists working in teaching hospitals were compared to answers given by gynecologists working in nonteaching hospitals. The data from this study were also compared to the data from our survey conducted in 2003 [15]. The chi-square test was used to compare proportions. Differences between groups were considered statistically significant at p < 0.05. All p values were two sided.

Findings

In 2009 a total of 837 gynecologists were registered in the Netherlands. After the first mailing, 409 questionnaires were returned. Another 87 gynecologists responded after the first reminder. A second reminder was sent, with a response of 89. In total a number of 585 (70%) gynecologists participated. Not all respondents answered all items of the questionnaire. Therefore subcalculations with different denominators were made.

Current practice

Of the 585 participating gynecologists, 455 (78%) performed polypectomy for endometrial polyps themselves. Table shows the current practice of removing endometrial polyps. An inpatient or day care setting was used routinely by 337 (74%) gynecologists, with general or regional anesthesia by 247 (54%) gynecologists. Removal under direct hysteroscopic vision was the most used method of polypectomy, used by 411 (91%) respondents. Removal under direct hysteroscopic visualization was practiced routinely with 5 Fr mechanical instruments, 5 Fr electrosurgical instruments, or resectoscope by 166 (40%), 181 (44%), and 174 (42%) respondents, respectively.

Table 1

Current practice in 2009 concerning removal of endometrial polyps

	Total	Teaching (n = 275)	Nonteaching (n = 180)	p value
Setting
-Inpatient/day care	337 (74)	193 (70)	144 (80)	0. 019
-Outpatient	153 (34)	118 (43)	35 (19)	<0.001
Anesthesia
-General/regional	247 (54)	133 (48)	114 (63)	0.002
-Local/no	211 (46)	152 (55)	59 (33)	<0.001
Method
-D&C	6 (1)	2 (1)	4 (2)	ns
-D&C after hysteroscopy	37 (8)	15 (6)	22 (12)	0. 010
-Direct hysteroscopic vision	411 (91)	257 (94)	154 (86)	0.005

Hysteroscopic vision	n = 411	n = 257	n = 154
Instrument
-5 Fr mechanical	166 (40)	102 (40)	64 (42)	ns
-5 Fr electrosurgical	181 (44)	122 (47)	59 (38)	ns
-Resectoscope	174 (42)	106 (41)	68 (44)	ns
-Morcellator	12 (3)	10 (4)	2 (1)	ns

Outpatient polypectomy was carried out by 153 (34%) of the respondents, and 211 (46%) used local or no anesthesia. Separating this last group, it shows that 76 gynecologists (17%) used local anesthesia vs. 145 (32%) no anesthesia (p < 0.001). Table shows the method of polyp removal vs. form of anesthesia. In case of D&C after hysteroscopic localization, more gynecologists used general or regional anesthesia than local or no anesthesia (13% vs. 1%, p < 0.001).

Table 2

Method of polyp removal versus form of anesthesia

	General/regional anesthesia	Local/no anesthesia	p value
D&C	3 (1)	1 (1)	ns
D&C following hysteroscopy	32 (13)	3 (1)	<0. 001
Under direct hysteroscopic vision	214 (86)	206 (98)	ns
Total	249	210

Teaching vs. nonteaching hospitals

In teaching hospitals, gynecologists removed polyps significantly more in an outpatient setting compared with gynecologists in nonteaching hospitals (43% vs. 19%, p < 0.001; Table ). Local or no anesthesia was more often used in teaching hospitals compared with nonteaching hospitals (55% vs. 33%, p < 0.001). Direct hysteroscopic vision was the most common method of polypectomy in both types of hospitals.

Comparison with practice in 2003

In 2003 and in 2009, an equal number of gynecologists (455) reported to remove endometrial polyps themselves. These results turned out this way by chance. In both years the majority of Dutch gynecologists performed polypectomy in an inpatient setting under general or regional anesthesia (Table ). Though, significantly less general or regional anesthesia (54% vs. 72%, p < 0.001) and more local or no anesthesia (46% vs. 22%, p < 0.001) is used in 2009 compared with 2003. This applies both for teaching and nonteaching hospitals (numbers not shown separately). In 2009, 145 gynecologists (32%) used no anesthesia vs. 21 (5%) in 2003 (p < 0.001). A shift towards the removal under direct hysteroscopic vision is seen in 2009 compared with 2003 (91% vs. 64%, p < 0.001), with a decrease in use of D&C (9% vs. 29%, p < 0.001). The 5 Fr electrosurgical instruments are more frequently used in 2009 compared with 2003 (44% vs. 19%, p < 0.001).

Table 3

Comparison numbers of 2009 with 2003

	Total 2009, n = 455	Total 2003, n = 455	p value
Setting
-Inpatient/day care	337 (74)	321 (71)	ns
-Outpatient	153 (34)	129 (28)	ns
Anesthesia
-General/regional	247 (54)	326 (72)	<0. 001
-Local/no	211 (46)	98 (22)	<0.001
Method
-D&C	6 (1)	17 (4)	0.03
-D&C after hysteroscopy	37 (8)	115 (25)	<0.001
-Direct hysteroscopic vision	411 (91)	290 (64)	<0.001

Hysteroscopic vision	2009, n = 411	2003, n = 290
Instrument
-5 Fr mechanical	166 (40)	197 (68)	<0. 001
-5 Fr electrosurgical	181 (44)	56 (19)	<0.001
-Resectoscope	174 (42)	159 (55)	0.001
-Morcellator	12 (3)	na	na

Discussion

Our survey shows that the majority of gynecologists in the Netherlands remove endometrial polyps in an inpatient setting, under direct hysteroscopic vision. More gynecologists in teaching hospitals perform polypectomy in an outpatient setting compared with nonteaching hospitals. Comparing current practice to the situation in 2003, we found an increase in hysteroscopic polyp removal with a decrease in D&C removal. Furthermore, we noted a decrease in the use of general or regional anesthesia and an increase in the number of gynecologists performing hysteroscopy with local or no anesthesia; no difference in the use of outpatient setting was noted. We also found an increase in the number of gynecologists using 5 French electrosurgical instruments.

There are two limitations that need to be addressed regarding the present study. First, our response rate is marginal. Our results should however be considered valid as a response rate of 70% is a level where the impact of nonresponse bias is negligible [25]. Moreover, the questionnaires were concise and met different criteria to achieve the best response rate. We met these criteria by using a short one-page questionnaire with return envelopes and reminders [26, 27].

The second limitation concerns the fact that we only considered the number of gynecologists removing polyps, and we did not display the number of polypectomies they performed. This could mean that few gynecologists perform polypectomies in an outpatient setting, but the major part of the number of polypectomies in the Netherlands (by a minor group of gynecologists) is performed outpatient. To get an impression of the number of uterine polypectomies per year, we sent all departments of gynecology in the Netherlands a letter and asked for the annual report of their department. However, the annual reports of the various hospitals differed in layout and classification. Some hospitals classified their therapeutic hysteroscopies in subcategories like hysteroscopic polypectomy, while others grouped them under the same denominator, without separation in numbers of polypectomies. We could therefore not include this information in our current survey.

In 2003 we hypothesized a tendency towards outpatient hysteroscopic removal of polyps for the future. Although we could not show such an increase directly in the number of gynecologists performing outpatient hysteroscopic polypectomy, our results imply that there is a tendency towards outpatient hysteroscopic polypectomy. We found an increase in the number of gynecologists performing polypectomy under direct hysteroscopic vision with local or no anesthesia and a decrease in D&C after hysteroscopy and the use of general or regional anesthesia. Considering the fact that an increase in local and no anesthesia was observed, it can only be concluded that more gynecologists are performing hysteroscopy as a “walk-in-walk-out” office procedure.

Hysteroscopic polypectomy seems to be integrated in the daily practice of most hospitals in the Netherlands [16]. Possible explanations for the shift towards outpatient hysteroscopic polypectomy can be mentioned on a speculative basis. First, the Dutch obstetrics and gynecology residency curriculum requires hysteroscopic polypectomy for graduation. The curriculum includes a basic surgical skill course with additionally the possibility to attend advanced courses and congresses on hysteroscopy. Each year many residents and gynecologists participate in these courses, which enhance the implementation of basic minimally invasive surgery skills training into the residency curriculum [28, 29]. Second, in 2002 hysteroscopic sterilization was introduced in the Netherlands. This technique was set in a “see-and-treat” setting with the use of 5 Fr working channel instruments. The use of this technique has probably had a positive influence on implementation of outpatient hysteroscopy for other indications. Third, literature shows that outpatient hysteroscopy is the most cost-effective method of hysteroscopy [24].

This progress in outpatient hysteroscopic polypectomy in the Netherlands is an advantage in medical practice. Literature shows that the best method of pain control for women undergoing traditional hysteroscopy is local anesthesia [30, 31]. However, a recent systematic review reported less pain during hysteroscopy in case of vaginoscopic approach (no anesthesia) compared with traditional hysteroscopic techniques, even with use of local anesthesia [32]. We showed a significant increase in the number of gynecologists using no anesthesia in 2009 compared with 2003. This makes the vaginoscopic approach of hysteroscopy more favorable.

Conclusion

In conclusion, this study shows that although hysteroscopy without anesthesia [32] and outpatient hysteroscopic polypectomy [19, 21–23] have been described in the literature to be highly successful, it is still not practiced on a large scale in the Netherlands. However, there is progress in outpatient hysteroscopic polypectomy. This implies that daily practice is catching up with the situation described in the literature.

Acknowledgment

We thank all gynecologists, who completed the questionnaire, for their cooperation.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Open Access

References

1. Karlsson B, Granberg S, Wikland M, Ylostalo P, Torvid K, Marsal K, Valentin L. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic multicenter study. Am J Obstet Gynecol. 1995;172(5):1488–1494. doi: 10.1016/0002-9378(95)90483-2. [PubMed] [CrossRef] [Google Scholar]2. O’Connell LP, Fries MH, Zeringue E, Brehm W. Triage of abnormal postmenopausal bleeding: a comparison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy. Am J Obstet Gynecol. 1998;178(5):956–961. doi: 10.1016/S0002-9378(98)70530-7. [PubMed] [CrossRef] [Google Scholar]3. Domingues AP, Lopes H, Dias I, Oliveira CF. Endometrial polyps in postmenopausal women. Acta Obstet Gynecol Scand. 2009;88(5):618–620. doi: 10.1080/00016340902818188. [PubMed] [CrossRef] [Google Scholar]4. Gale A, Dey P. Postmenopausal bleeding. Menopause Int. 2009;15(4):160–164. doi: 10.1258/mi.2009.009039. [PubMed] [CrossRef] [Google Scholar]5. Kassab A, Trotter P, Fox R. Risk of cancer in symptomatic postmenopausal women with endometrial polyps at scan. J Obstet Gynaecol. 2008;28(5):522–525. doi: 10.1080/01443610802097625. [PubMed] [CrossRef] [Google Scholar]6. Ferrazzi E, Zupi E, Leone FP, Savelli L, Omodei U, Moscarini M, Barbieri M, Cammareri G, Capobianco G, Cicinelli E, Coccia ME, Donarini G, Fiore S, Litta P, Sideri M, Solima E, Spazzini D, Testa AC, Vignali M. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol. 2009;200(3):235–236. doi: 10.1016/j.ajog.2008.09.876. [PubMed] [CrossRef] [Google Scholar]7. Golan A, Cohen-Sahar B, Keidar R, Condrea A, Ginath S, Sagiv R. Endometrial polyps: symptomatology, menopausal status and malignancy. Gynecol Obstet Invest. 2010;70(2):107–112. doi: 10.1159/000298767. [PubMed] [CrossRef] [Google Scholar]8. Clark TJ, Khan KS, Gupta JK. Current practice for the treatment of benign intrauterine polyps: a national questionnaire survey of consultant gynaecologists in UK. Eur J Obstet Gynecol Reprod Biol. 2002;103(1):65–67. doi: 10.1016/S0301-2115(02)00011-8. [PubMed] [CrossRef] [Google Scholar]9. Timmermans A, Veersema S, van Kerkvoorde TC, van der Voet LF, Opmeer BC, Bongers MY, Mol BW. Should endometrial polyps be removed in patients with postmenopausal bleeding?—an assessment of study designs and report of a failed randomised controlled trial (ISRCTN73825127) BJOG. 2009;116(10):1391–1395. doi: 10.1111/j.1471-0528.2009.02234.x. [PubMed] [CrossRef] [Google Scholar]10. Lieng M, Istre O, Sandvik L, Engh V, Qvigstad E. Clinical effectiveness of transcervical polyp resection in women with endometrial polyps: randomized controlled trial. J Minim Invasive Gynecol. 2010;17(3):351–357. doi: 10.1016/j.jmig.2010.01.019. [PubMed] [CrossRef] [Google Scholar]11. Nathani F, Clark TJ. Uterine polypectomy in the management of abnormal uterine bleeding: a systematic review. J Minim Invasive Gynecol. 2006;13(4):260–268. doi: 10.1016/j.jmig.2006.03.015. [PubMed] [CrossRef] [Google Scholar]12. Lieng M, Istre O, Qvigstad E. Treatment of endometrial polyps: a systematic review. Acta Obstet Gynecol Scand. 2010;89(8):992–1002. doi: 10.3109/00016349.2010.493196. [PubMed] [CrossRef] [Google Scholar]13. Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001;80(12):1131–1136. doi: 10.1034/j.1600-0412.2001.801210.x. [PubMed] [CrossRef] [Google Scholar]14. Gebauer G, Hafner A, Siebzehnrubl E, Lang N. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol. 2001;184(2):59–63. doi: 10.1067/mob.2001.108332. [PubMed] [CrossRef] [Google Scholar]15. Timmermans A, van Dongen H, Mol BW, Veersema S, Jansen FW. Hysteroscopy and removal of endometrial polyps: a Dutch survey. Eur J Obstet Gynecol Reprod Biol. 2008;138(1):76–79. doi: 10.1016/j.ejogrb.2007.05.016. [PubMed] [CrossRef] [Google Scholar]16. van Dongen H, Kolkman W, Jansen FW. Implementation of hysteroscopic surgery in The Netherlands. Eur J Obstet Gynecol Reprod Biol. 2007;132(2):232–236. doi: 10.1016/j.ejogrb.2006.04.016. [PubMed] [CrossRef] [Google Scholar]17. Bettocchi S, Nappi L, Ceci O, Selvaggi L. Office hysteroscopy. Obstet Gynecol Clin N Am. 2004;31(3):641–654. doi: 10.1016/j.ogc.2004.05.007. [PubMed] [CrossRef] [Google Scholar]18. Garuti G, Cellani F, Colonnelli M, Grossi F, Luerti M. Outpatient hysteroscopic polypectomy in 237 patients: feasibility of a one-stop “see-and-treat” procedure. J Am Assoc Gynecol Laparosc. 2004;11(4):500–504. doi: 10.1016/S1074-3804(05)60083-7. [PubMed] [CrossRef] [Google Scholar]19. Marsh FA, Rogerson LJ, Duffy SR. A randomised controlled trial comparing outpatient versus daycase endometrial polypectomy. BJOG. 2006;113(8):896–901. doi: 10.1111/j.1471-0528.2006.00967.x. [PubMed] [CrossRef] [Google Scholar]20. Ghaly S, de Abreu LR, Abbott JA. Audit of endometrial biopsy at outpatient hysteroscopy. Aust N Z J Obstet Gynaecol. 2008;48(2):202–206. doi: 10.1111/j.1479-828X.2008.00834.x. [PubMed] [CrossRef] [Google Scholar]21. Litta P, Cosmi E, Saccardi C, Esposito C, Rui R, Ambrosini G. Outpatient operative polypectomy using a 5 mm-hysteroscope without anaesthesia and/or analgesia: advantages and limits. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):210–214. doi: 10.1016/j.ejogrb.2007.11.008. [PubMed] [CrossRef] [Google Scholar]22. Siristatidis C, Chrelias C. Feasibility of office hysteroscopy through the “see and treat technique” in private practice: a prospective observational study. Arch Gynecol Obstet. 2010;283(4):819–823. doi: 10.1007/s00404-010-1431-3. [PubMed] [CrossRef] [Google Scholar]23. Di Spiezio SA, Bettocchi S, Spinelli M, Guida M, Nappi L, Angioni S, Sosa Fernandez LM, Nappi C. Review of new office-based hysteroscopic procedures 2003–2009. J Minim Invasive Gynecol. 2010;17(4):436–448. doi: 10.1016/j.jmig.2010.03.014. [PubMed] [CrossRef] [Google Scholar]24. Saridogan E, Tilden D, Sykes D, Davis N, Subramanian D. Cost-analysis comparison of outpatient see-and-treat hysteroscopy service with other hysteroscopy service models. J Minim Invasive Gynecol. 2010;17(4):518–525. doi: 10.1016/j.jmig.2010.03.009. [PubMed] [CrossRef] [Google Scholar]25. Lydeards S. Commentary: avoid surveys masquerading as research. BMJ. 1996;313:733–734. doi: 10.1136/bmj.313.7059.733. [CrossRef] [Google Scholar]26. Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, Kwan I, Cooper R. Methods to increase response rates to postal questionnaires. Cochrane Database Syst Rev. 2007;2:MR000008. [PubMed] [Google Scholar]27. VanGeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof. 2007;30(4):303–321. doi: 10.1177/0163278707307899. [PubMed] [CrossRef] [Google Scholar]28. Hiemstra E, Kolkman W, Jansen FW. Skills training in minimally invasive surgery in Dutch obstetrics and gynecology residency curriculum. Gynecol Surg. 2008;5(4):321–325. doi: 10.1007/s10397-008-0402-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]29. van Dongen H, Emanuel MH, Wolterbeek R, Trimbos JB, Jansen FW. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomized controlled pilot study among residents in training. J Minim Invasive Gynecol. 2008;15(4):466–471. doi: 10.1016/j.jmig.2008.02.002. [PubMed] [CrossRef] [Google Scholar]30. Ahmad G, Attarbashi S, O’Flynn H, Watson AJ. Pain relief in office gynaecology: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2011;155(1):3–13. doi: 10.1016/j.ejogrb.2010.11.018. [PubMed] [CrossRef] [Google Scholar]31. Cooper NA, Khan KS, Clark TJ. Local anaesthesia for pain control during outpatient hysteroscopy: systematic review and meta-analysis. BMJ. 2010;340:c1130. doi: 10.1136/bmj.c1130. [PMC free article] [PubMed] [CrossRef] [Google Scholar]32. Cooper NA, Smith P, Khan KS, Clark TJ. Vaginoscopic approach to outpatient hysteroscopy: a systematic review of the effect on pain. BJOG. 2010;117(5):532–539. doi: 10.1111/j.1471-0528.2010.02503.x. [PubMed] [CrossRef] [Google Scholar]

Current practice in the removal of benign endometrial polyps: a Dutch survey

Gynecol Surg. 2012; 9(2): 163–168.

,¹,^1,²,³,² and ²

Lotte J. E. W. van Dijk

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

Maria C. Breijer

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

Sebastiaan Veersema

³Department of Obstetrics & Gynecology, St. Antonius Hospital, Nieuwegein, The Netherlands

Ben W. J. Mol

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

Anne Timmermans

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

³Department of Obstetrics & Gynecology, St. Antonius Hospital, Nieuwegein, The Netherlands

Corresponding author.

Received 2011 Aug 15; Accepted 2011 Oct 1.

This article has been cited by other articles in PMC.

Abstract

Keywords: Polypectomy, Hysteroscopy, Inpatient, Outpatient

Background

Materials and methods

Statistical analysis

Findings

Current practice

Table 1

Current practice in 2009 concerning removal of endometrial polyps

	Total	Teaching (n = 275)	Nonteaching (n = 180)	p value
Setting
-Inpatient/day care	337 (74)	193 (70)	144 (80)	0.019
-Outpatient	153 (34)	118 (43)	35 (19)	<0.001
Anesthesia
-General/regional	247 (54)	133 (48)	114 (63)	0.002
-Local/no	211 (46)	152 (55)	59 (33)	<0.001
Method
-D&C	6 (1)	2 (1)	4 (2)	ns
-D&C after hysteroscopy	37 (8)	15 (6)	22 (12)	0.010
-Direct hysteroscopic vision	411 (91)	257 (94)	154 (86)	0.005

Hysteroscopic vision	n = 411	n = 257	n = 154
Instrument
-5 Fr mechanical	166 (40)	102 (40)	64 (42)	ns
-5 Fr electrosurgical	181 (44)	122 (47)	59 (38)	ns
-Resectoscope	174 (42)	106 (41)	68 (44)	ns
-Morcellator	12 (3)	10 (4)	2 (1)	ns

Table 2

Method of polyp removal versus form of anesthesia

	General/regional anesthesia	Local/no anesthesia	p value
D&C	3 (1)	1 (1)	ns
D&C following hysteroscopy	32 (13)	3 (1)	<0.001
Under direct hysteroscopic vision	214 (86)	206 (98)	ns
Total	249	210

Teaching vs. nonteaching hospitals

Comparison with practice in 2003

Table 3

Comparison numbers of 2009 with 2003

	Total 2009, n = 455	Total 2003, n = 455	p value
Setting
-Inpatient/day care	337 (74)	321 (71)	ns
-Outpatient	153 (34)	129 (28)	ns
Anesthesia
-General/regional	247 (54)	326 (72)	<0.001
-Local/no	211 (46)	98 (22)	<0.001
Method
-D&C	6 (1)	17 (4)	0.03
-D&C after hysteroscopy	37 (8)	115 (25)	<0.001
-Direct hysteroscopic vision	411 (91)	290 (64)	<0.001

Hysteroscopic vision	2009, n = 411	2003, n = 290
Instrument
-5 Fr mechanical	166 (40)	197 (68)	<0.001
-5 Fr electrosurgical	181 (44)	56 (19)	<0.001
-Resectoscope	174 (42)	159 (55)	0.001
-Morcellator	12 (3)	na	na

Discussion

Conclusion

Acknowledgment

We thank all gynecologists, who completed the questionnaire, for their cooperation.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Open Access

References

Current practice in the removal of benign endometrial polyps: a Dutch survey

Gynecol Surg. 2012; 9(2): 163–168.

,¹,^1,²,³,² and ²

Lotte J. E. W. van Dijk

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

Maria C. Breijer

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

Sebastiaan Veersema

³Department of Obstetrics & Gynecology, St. Antonius Hospital, Nieuwegein, The Netherlands

Ben W. J. Mol

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

Anne Timmermans

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

¹Department of Obstetrics & Gynecology, TweeSteden Hospital, Tilburg, The Netherlands

²Department of Obstetrics & Gynecology, Academic Medical Center, Amsterdam, The Netherlands

³Department of Obstetrics & Gynecology, St. Antonius Hospital, Nieuwegein, The Netherlands

Corresponding author.

Received 2011 Aug 15; Accepted 2011 Oct 1.

This article has been cited by other articles in PMC.

Abstract

Keywords: Polypectomy, Hysteroscopy, Inpatient, Outpatient

Background

Materials and methods

Statistical analysis

Findings

Current practice

Table 1

Current practice in 2009 concerning removal of endometrial polyps

	Total	Teaching (n = 275)	Nonteaching (n = 180)	p value
Setting
-Inpatient/day care	337 (74)	193 (70)	144 (80)	0.019
-Outpatient	153 (34)	118 (43)	35 (19)	<0.001
Anesthesia
-General/regional	247 (54)	133 (48)	114 (63)	0.002
-Local/no	211 (46)	152 (55)	59 (33)	<0.001
Method
-D&C	6 (1)	2 (1)	4 (2)	ns
-D&C after hysteroscopy	37 (8)	15 (6)	22 (12)	0.010
-Direct hysteroscopic vision	411 (91)	257 (94)	154 (86)	0.005

Hysteroscopic vision	n = 411	n = 257	n = 154
Instrument
-5 Fr mechanical	166 (40)	102 (40)	64 (42)	ns
-5 Fr electrosurgical	181 (44)	122 (47)	59 (38)	ns
-Resectoscope	174 (42)	106 (41)	68 (44)	ns
-Morcellator	12 (3)	10 (4)	2 (1)	ns

Table 2

Method of polyp removal versus form of anesthesia

	General/regional anesthesia	Local/no anesthesia	p value
D&C	3 (1)	1 (1)	ns
D&C following hysteroscopy	32 (13)	3 (1)	<0.001
Under direct hysteroscopic vision	214 (86)	206 (98)	ns
Total	249	210

Teaching vs. nonteaching hospitals

Comparison with practice in 2003

Table 3

Comparison numbers of 2009 with 2003

	Total 2009, n = 455	Total 2003, n = 455	p value
Setting
-Inpatient/day care	337 (74)	321 (71)	ns
-Outpatient	153 (34)	129 (28)	ns
Anesthesia
-General/regional	247 (54)	326 (72)	<0.001
-Local/no	211 (46)	98 (22)	<0.001
Method
-D&C	6 (1)	17 (4)	0.03
-D&C after hysteroscopy	37 (8)	115 (25)	<0.001
-Direct hysteroscopic vision	411 (91)	290 (64)	<0.001

Hysteroscopic vision	2009, n = 411	2003, n = 290
Instrument
-5 Fr mechanical	166 (40)	197 (68)	<0.001
-5 Fr electrosurgical	181 (44)	56 (19)	<0.001
-Resectoscope	174 (42)	159 (55)	0.001
-Morcellator	12 (3)	na	na

Discussion

Conclusion

Acknowledgment

We thank all gynecologists, who completed the questionnaire, for their cooperation.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Open Access

References

D&C (Dilation and Curettage) Procedure: Surgery and Recovery

Dilation and curettage (D&C) is a brief surgical procedure in which the cervix is dilated and a special instrument is used to scrape the uterine lining. Knowing what to expect before, during, and after a D&C may help ease your worries and make the process go more smoothly. Here’s what you need to know.

Reasons for a D&C

You may need a D&C for one of several reasons. It’s done to:

Remove tissue in the uterus during or after a miscarriage or abortion or to remove small pieces of placenta after childbirth. This helps prevent infection or heavy bleeding.
Diagnose or treat abnormal uterine bleeding. A D&C may help diagnose or treat growths such as fibroids, polyps, hormonal imbalances, or uterine cancer. A sample of uterine tissue is viewed under a microscope to check for abnormal cells.

What to Expect When Having a D&C

You can have a D&C in your doctor’s office, an outpatient clinic, or the hospital. It usually takes only 10 to 15 minutes, but you may stay in the office, clinic, or hospital for up to five hours.

Before a D&C, you will have a complete history taken and sign a consent form. Ask your doctor any questions you have about the D&C. Be sure to tell the doctor if:

You suspect you are pregnant.
You are sensitive or allergic to any medications, iodine, or latex.
You have a history of bleeding disorders or are taking any blood-thinning drugs.

You will receive anesthesia, which your doctor will discuss with you. The type you have depends on the procedure you need.

If you have general anesthesia, you will not be awake during the procedure.
If you have spinal or epidural (regional) anesthesia, you will not have feeling from the waist down.
If you have local anesthesia, you will be awake and the area around you cervix will be numbed.

Before the D&C, you may need to remove clothing, put on a gown, and empty your bladder.

During a D&C, you lie on your back and place your legs in stirrups like during a pelvic exam. Then the doctor inserts a speculum into the vagina and holds the cervix in place with a clamp. Although the D&C involves no stitches or cuts, the doctor cleanses the cervix with an antiseptic solution.

A D&C involves two main steps:

Dilation involves widening the opening of the lower part of the uterus (the cervix) to allow insertion of an instrument. The doctor may insert a slender rod (laminaria) into the opening beforehand or use a medication before the procedure to soften the cervix and cause it to widen.
Curettage involves scraping the lining and removing uterine contents with a long, spoon-shaped instrument (a curette). The doctor may also use a cannula to suction any remaining contents from the uterus. This can cause some cramping. A tissue sample then goes to a lab for examination.

Sometimes other procedures are performed along with a D&C. For example, your doctor may insert a slender device to view the inside of the uterus (called hysteroscopy). They may remove a polyp or fibroid.

After a D&C, there are possible side effects and risks. Common side effects include:

Cramping
Spotting or light bleeding

Complications such as a damaged cervix and perforated uterus or bladder and blood vessels are rare. But be sure to contact your doctor if you have any of the following symptoms after a D&C:

Heavy or prolonged bleeding or blood clots
Fever
Pain
Abdominal tenderness
Foul-smelling discharge from the vagina

In very rare cases, scar tissue (adhesions) may form inside the uterus. Called Asherman’s syndrome, this may cause infertility and changes in menstrual flow. Surgery can repair this problem, so be sure to report any abnormal menstrual changes after a D&C.

Recovery After a D&C

After a D&C, you will need someone to take you home. If you had general anesthesia, you may feel groggy for a while and have some brief nausea and vomiting. You can return to regular activities within one or two days. In the meantime, ask your doctor about any needed restrictions. You may also have mild cramping and light spotting for a few days. This is normal. You may want to wear a sanitary pad for spotting and take pain relievers for pain.

You can expect a change in the timing of your next menstrual period. It may come either early or late. To prevent bacteria from entering your uterus, delay sex and use of tampons until your doctor says it’s OK.

See your doctor for a follow-up visit and schedule any further treatment that’s needed. If any tissue was sent for a biopsy, ask your doctor when to expect results. They are usually available within several days.

Uterine Polyps Treatment | Tennessee Reproductive Medicine

Uterine polyps at a glance

Uterine polyps, also known as endometrial polyps, are bulb-shaped growths of endometrial tissue that develop in the uterus, attaching to the uterine lining by a stalk.
Polyps can also develop in the cervix or inside the cervical canal, as well as slip down through the uterus opening into the vagina.
Polyps are usually noncancerous, but may become cancerous over time.
The exact cause of these polyps is unknown, but the hormone estrogen seems to promote their growth.
Uterine polyps are most often seen in women who have gone through menopause, but can develop in younger women, sometimes causing infertility. It is not clear if they cause recurrent miscarriage.
Polyps often do not show symptoms, but abnormal uterine bleeding is the most common symptom.
Some polyps do not require treatment; symptomatic polyps can be treated through medication or removal, and do not usually return after treatment.

Causes of these polyps

Uterine (endometrial) polyps are similar to uterine fibroids, most likely developing due to an imbalance of the hormone estrogen. Excess endometrial tissue develops in response to estrogen, causing soft uterine polyps to grow from the uterine lining. Polyps are more frequently seen in perimenopausal or postmenopausal women, but can occur in younger women as well.

Endometrial polyps are more common in women with high blood pressure (hypertension), who are overweight, or who are taking tamoxifen (a medication used for treating breast cancer).

Could polyps be causing conception problems?

Tennessee Reproductive Medicine can help you with expert diagnosis and treatment.
Request Appointment

Symptoms

Many women with polyps do not experience symptoms, but the most common symptoms include:

Irregular periods or menstrual bleeding
Heavy menstrual bleeding
Vaginal bleeding after menopause
Bleeding between periods
Bleeding after sex

When these symptoms are severe, the woman should visit her doctor, as these may also indicate endometrial cancer.

These polyps can also cause infertility or, possibly, miscarriages by preventing the fertilized egg from implanting in the uterine wall correctly. Research published by the National Institutes of Health indicates that endometrial (uterine) polyps are a factor in about 35% of female infertility.

Treatment of uterine polyps

Treatment for uterine polyps ranges from observation of the polyps (to make sure they do not develop worrisome features) to surgical removal. Hormonal medication such as progestin may relieve symptoms and shrink the polyp, but symptoms generally return once the medication is stopped.

Surgical treatment

A few minimally invasive surgical techniques can treat polyps in the uterus. The preferred method to treat polyps is hysteroscopy, a surgical procedure in which a tube connected to a camera (hysteroscope) is inserted through the cervix and into the uterus so that the polyp can be visualized directly and removed with precision. This procedure does not involve any incisions and can be completed as an outpatient with minimal recovery time needed.

A physician may also perform cervical dilation and curettage, also known as a D&C, by using a long metal tool to scrape the uterine lining, either to obtain a sample for diagnosis or remove the polyp. A D&C is not the preferred method of treatment, because it is possible to incompletely remove the polyp. Incomplete removal can result in recurrence. In addition, a D&C can create scar tissue within the uterus, which can lead to infertility.

Removed polyps may also be tested for cancer cells to determine if further treatment is necessary. Once removed, polyps generally do not resurface.

Hysteroscopy – NHS

A hysteroscopy is a procedure used to examine the inside of the womb (uterus).

It’s carried out using a hysteroscope, which is a narrow telescope with a light and camera at the end. Images are sent to a monitor so your doctor or specialist nurse can see inside your womb.

The hysteroscope is passed into your womb through your vagina and cervix (entrance to the womb), which means no cuts need to be made in your skin.

When a hysteroscopy may be carried out

A hysteroscopy can be used to:

A procedure called dilatation and curettage (D&C) used to be common to examine the womb and remove abnormal growths, but now hysteroscopies are carried out instead.

What happens during a hysteroscopy

A hysteroscopy is usually carried out on an outpatient or day-case basis. This means you do not have to stay in hospital overnight.

It may not be necessary to use anaesthetic for the procedure, although local anaesthetic (where medication is used to numb your cervix) is sometimes used.

General anaesthetic may be used if you’re having treatment during the procedure or you would prefer to be asleep while it’s carried out.

A hysteroscopy can take up to 30 minutes in total, although it may only last around 5 to 10 minutes if it’s just being done to diagnose a condition or investigate symptoms.

Read more about what happens during a hysteroscopy.

Is a hysteroscopy painful?

This seems to vary considerably between women. Some women feel no or only mild pain during a hysteroscopy, but for others the pain can be severe.

If you find it too uncomfortable, tell the doctor or nurse. They can stop the procedure at any time.

If you’re worried, speak to the doctor or nurse before having the procedure about what to expect and ask them about pain relief options.

Recovering from a hysteroscopy

Most women feel able to return to their normal activities the following day, although some women return to work the same day.

You may wish to have a few days off to rest if general anaesthetic was used.

While you’re recovering:

you can eat and drink as normal straight away
you may experience cramping that’s similar to period pain and some spotting or bleeding for a few days – this is normal and nothing to worry about unless it’s heavy
you should avoid having sex for a week, or until any bleeding has stopped, to reduce the risk of infection (see below)

Your doctor or nurse will discuss the findings of the procedure with you before you leave hospital.

Read more about what happens after a hysteroscopy.

Risks of a hysteroscopy

A hysteroscopy is generally very safe but, like any procedure, there is a small risk of complications. The risk is higher for women who have treatment during a hysteroscopy.

Some of the main risks associated with a hysteroscopy are:

accidental damage to the womb – this is uncommon but may require treatment with antibiotics in hospital or, in rare cases, another operation to repair it
accidental damage to the cervix – this is rare and can usually be easily repaired
excessive bleeding during or after surgery – this can occur if you had treatment under general anaesthetic and can be treated with medication or another procedure; very rarely, it may be necessary to remove the womb (hysterectomy)
infection of the womb – this can cause smelly vaginal discharge, a fever and heavy bleeding; it can usually be treated with a short course of antibiotics from your GP
feeling faint – this affects 1 in every 200 women who have a hysteroscopy carried out without an anaesthetic or just a local anaesthetic

A hysteroscopy will only be carried out if the benefits are thought to outweigh the risks.

Alternatives to hysteroscopy

Your womb could also be examined by using a:

pelvic ultrasound – where a small probe is inserted in the vagina and uses sound waves to produce an image of the inside of your womb
endometrial biopsy – when a narrow tube is passed through your cervix into your womb, with suction used to remove a sample of your womb’s lining

These alternatives may be performed alongside a hysteroscopy, but do not provide as much information and can’t be used to treat problems in the same way as a hysteroscopy.

Page last reviewed: 05 December 2018
Next review due: 05 December 2021

Uterine Cancer: Diagnosis | Cancer.Net

ON THIS PAGE: You will find a list of common tests, procedures, and scans that doctors use to find the cause of a medical problem. Use the menu to see other pages.

Doctors use many tests to find, or diagnose, cancer. They do tests to learn whether cancer has spread to a different part of the body from where it started. If this happens, it is called metastasis. For example, imaging tests such as CT scans (see below) can show if the cancer has spread. Imaging tests show pictures of the inside of the body. Doctors may also do tests to learn which treatments could work best.

For most types of cancer, a biopsy is the only sure way for the doctor to know if an area of the body has cancer. In a biopsy, the doctor takes a small sample of tissue for testing in a laboratory. If a biopsy is not possible, the doctor may suggest other tests that will help make a diagnosis.

This section describes options for diagnosing uterine cancer. Not all tests listed will be used for every woman. Your doctor may consider these factors when choosing a diagnostic test:

The type of cancer suspected
Your signs and symptoms
Your age and general health
The results of previous medical tests

In addition to a physical examination, the following tests may be used to diagnose uterine cancer:

Pelvic examination. The doctor feels the uterus, vagina, ovaries, and rectum to check for any unusual findings. A Pap test, often done with a pelvic examination, is primarily used to check for cervical cancer. Sometimes a Pap test may find abnormal glandular cells, which are caused by uterine cancer.
Endometrial biopsy. A biopsy is the removal of a small amount of tissue for examination under a microscope. Other tests can suggest that cancer is present, but only a biopsy can make a definite diagnosis. A pathologist analyzes the sample(s). A pathologist is a doctor who specializes in interpreting laboratory tests and evaluating cells and tissue samples to diagnose disease.
For an endometrial biopsy, the doctor removes a small sample of tissue with a very thin tube. The tube is inserted into the uterus through the cervix, and the tissue is removed with suction. This process takes a few minutes. Afterward, the woman may have cramps and vaginal bleeding. These symptoms should go away soon and can be reduced by taking a nonsteroidal anti-inflammatory drug (NSAID) as directed by the doctor. Endometrial biopsy is often a very accurate way to diagnose uterine cancer. People who have abnormal vaginal bleeding before the test may still need a dilation and curettage (D&C; see below), even if no abnormal cells are found during the biopsy.
Dilation and curettage (D&C). A D&C is a procedure to remove tissue samples from the uterus. A woman is given anesthesia during the procedure to block the awareness of pain. A D&C is often done in combination with a hysteroscopy so the doctor can view the lining of the uterus during the procedure. During a hysteroscopy, the doctor inserts a thin, flexible tube with a light on it through the cervix into the vagina and uterus. After endometrial tissue has been removed, during a biopsy or D&C, the sample is checked by a pathologist for cancer cells, endometrial hyperplasia, and other conditions.
Transvaginal ultrasound. An ultrasound uses sound waves to create a picture of internal organs. In a transvaginal ultrasound, an ultrasound wand is inserted into the vagina and aimed at the uterus to take pictures. If the endometrium looks too thick, the doctor may decide to perform a biopsy (see above).
Computed tomography (CT or CAT) scan. A CT scan takes pictures of the inside of the body using x-rays taken from different angles. A computer combines these pictures into a detailed, 3-dimensional image that shows any abnormalities or tumors. A CT scan can be used to measure the tumor’s size. Sometimes, a special dye called a contrast medium is given before the scan to provide better detail on the image. This dye can be injected into a patient’s vein or given as a pill or liquid to swallow.
Magnetic resonance imaging (MRI). An MRI uses magnetic fields, not x-rays, to produce detailed images of the body. MRI can be used to measure the tumor’s size. Like with a CT scan, a special dye called a contrast medium can be given intravenously or orally before the scan to create a clearer picture. MRI is very useful for getting detailed images if the treatment plan will include hormone management (see Types of Treatment). MRI is often used in women with low-grade uterine cancer (see Stages and Grades) to see how far the cancer has grown into the wall of the uterus. Knowing this can help determine whether a woman’s fertility can be preserved.
Molecular testing of the tumor. Your doctor may recommend running laboratory tests on a tumor sample to identify specific genes, proteins, and other factors unique to the tumor. Results of these tests can help determine your treatment options.

After diagnostic tests are done, your doctor will review all of the results with you. If the diagnosis is cancer, additional testing will be performed to discover how far the disease has grown. This helps to categorize the disease by stage and grade and directs the type of treatment that will be needed.

The next section in this guide is Stages and Grades. It explains the system doctors use to describe the extent of the disease. Use the menu to choose a different section to read in this guide.

Polyp of the cervical canal

Polyp of the cervical canal disrupts the functioning of the cervix, contributes to the formation of a chronic focus of infection and the appearance of spotting in the intermenstrual periods. Such benign neoplasms are found in 20-25% of women, including during pregnancy. At the same time, timely diagnostics and a correctly selected treatment plan guarantee a cure.

In our clinics you can:

For more details and for any questions, please contact the number indicated on the website

Do you suspect you have symptoms of polyps? Do you want to undergo a comprehensive diagnosis of the reproductive system? Family Medical Center “Imma” will take care of your health.Make an appointment with our specialists at a convenient time – we work from 9.00 to 21.00.

What is a polyp of the cervical canal and how is it dangerous?

This is a benign neoplasm that appears in the lumen of the cervix from the connective tissue. Outside, polyps are covered with flat or tall cylindrical growths of the epithelium. They are attached to the cervical canal with a thin or thick leg closer to the external os of the cervix and rarely polyps are visible in the vaginal lumen (tumors on a long leg are visible).

Symptoms of the polyp of the cervical canal

As a rule, the disease has no characteristic symptoms. If the neoplasms are small and grow on a thick low leg, they are not felt by the patient and are not visible to the doctor during a standard examination. Polyps are detected in the diagnosis of other diseases of the reproductive system – according to statistics, in more than 70 cases of the formation of polyps of the cervical canal, a woman also exhibits other diseases.

Symptoms of the disease are manifested in each woman in different ways – this is influenced not only by the physiological features, but also by the structure of the formations.

Fibrous neoplasms have virtually no symptoms. All due to the fact that such polyps do not have glands, which means they do not secrete mucus. Their dense and poorly vascularized structure is quite difficult to injure, respectively, the risk of bleeding is reduced to almost zero.
Glandular polyps of the cervical canal, on the contrary, produce mucus and even increase intermenstrual bleeding. At the same time, all the discharge is rather scanty in nature – all because of their small size (up to 10 mm).

Glandular fibrous polyps of the cervical canal are mixed formations, so their symptoms are especially pronounced. The woman feels pain, bleeding appears after intercourse, characteristic intermenstrual bleeding.

What provokes the disease: the causes of the polyp of the cervical canal

Channel trauma

Any damage to the cervical canal can change the structural composition of its epithelium – abortions, improperly installed intrauterine devices.In order for a polyp to form on the membrane, it is not necessary to receive a major injury – even a microscopic wound can cause a neoplasm to form.

Changes in the surface of the cervix

True and false erosion, leukoplakia.

Sexual infections

Trichomoniasis, gonorrhea, chlamydia and other STIs weaken a woman’s immune system and affect the cervical canal, disrupt the natural composition of the mucus found there.As a result, local inflammation forms, the mucous membrane becomes loose, prone to injury. In some cases, for protection, it can begin to increase its own area, as a result of forming a polyp or a group of them.

Non-specific infections

Vulvovaginitis, vaginitis, cervicitis, endometritis, endomyometritis.

Violation of the vaginal microflora

An imbalance of bacteria leads to fluctuations in the level of acidity, a favorable environment is formed for the growth of the epithelial layer of the cervical canal.

Ovarian dysfunction

An excess of estrogen accumulates, there is a powerful stimulation of the growth of the epithelium, which lines the cervical zone. Often, the disease is accompanied by fibroids, endometrium and endometriosis.

External factors and endocrine processes

Obesity, diabetes mellitus, overwork and stress.

Physiological processes

Hormonal surges during adolescence, pregnancy, lactation and menopause.

What is the danger of the disease: the consequences of the polyp of the cervical canal

Polyps can transform into benign formations.
The risk of developing uterine bleeding increases.
If a polyp is found during pregnancy, and the treatment was not prescribed correctly, a spontaneous abortion is possible.
Necrosis of a tumor or neglect of treatment can cause death of adjacent tissues, blood poisoning.

Should a cervical polyp be removed? Polyps are subject to mandatory removal.The exception is small neoplasms. In any case, polyps cannot be eliminated on their own; at least drug treatment of the tumor is necessary.

Warn, do not heal!

Get diagnostics of cervical canal polyps in our medical center. We perform colposcopy, ultrasound, knife biopsy of the cervix. After a gynecological examination with a mirror and taking an anamnesis, the doctor will determine the necessary list of examinations and, based on their results, select therapy.

Make an appointment – we will be glad to see you in any of the six Imma clinics in Moscow.

Removal of polyp of the cervical canal and cervix

Removal of the polyp of the cervical canal and cervix with simultaneous curettage of the mucous membrane of the cervical canal and uterine cavity in Operating room No. 1, Alexandrov

The anatomical structure of the cervical canal defines the organ as an elongated cavity that connects the uterus and vagina.Polyps are benign growths – an abnormal proliferation of cells and tissues under the mucous membranes. Polyps of the cervical canal statically account for about a third of all benign neoplasms in women, but one should not be afraid of such a diagnosis. Modern methods of surgical treatment allow painless and safe removal of polypous growths.

Readings

Removal of a polyp in the uterus is prescribed in case of ineffectiveness of conservative treatment, with an increase in the clinical picture or an increase in the size of the formation – the diameter of the polyp becomes more than 5 mm.

Contraindications

There are a number of conditions in which removal of polyps is not carried out for medical reasons:

detection of various inflammatory processes in the genitals – vaginitis, vulvitis, endometritis;
pregnancy, breastfeeding – it is not recommended to carry out surgical interventions before the end of lactation;
menstruation – you must wait 7-8 days of the cycle;
oncological diseases – if a malignant proliferation of cells is determined by histological examination, it is necessary to start treating this neoplasm;
high risks of uterine bleeding – with various concomitant diseases of the uterus or during menopause.

Also, some chronic diseases raise a number of concerns. Diabetes mellitus, renal failure, liver dysfunction and other systemic pathologies are considered relative contraindications for surgery.

Preparation

Preparation for surgery includes various stages of general and special examination. First, it is necessary to carry out standard diagnostic measures to determine the safety of the intervention, then the gynecologist prescribes specific diagnostic methods to determine risk factors from the genital organs:

vaginal smear for the determination of pathogenic microorganisms;
PCR reaction for accurate detection of HIV, herpes simplex virus, papilloma;
Ultrasound examination using a vaginal probe;
hysteroscopy – endoscopic examination of the uterine cavity.

Immediately before the operation, you should take hygienic measures, shave off the hair in the area of the external genital organs, and on the day of the operation, refuse to eat and drink.

Procedure

The operation is performed under local anesthesia with a small amount of education and under general anesthesia in case of severe polyposis. The hysteroscope allows you to accurately determine the localization of the polyp, then a special attachment safely removes it. After that, curettage is performed – a procedure for the diagnostic assessment of the contents of the uterine cavity.The removed tissue is examined to determine the cellular composition of the polyp.

Recovery

Rehabilitation is quick and easy, it is important to take antibacterial and anti-inflammatory drugs, if necessary, pain relievers. The doctor can prescribe physiotherapy, as well as draw up an examination plan to assess the result of the operation.

Rehabilitation lasts about 4 weeks. During this period, you need to take care of your own health as much as possible.

What is the danger of refusal from operation

Some women prefer non-traditional or drug-based methods for removing polyps, but herbal treatment, vaginal suppositories or psychotherapy are not able to get rid of pathological formation, and the clinical effectiveness of these methods has not been proven.By itself, the polyp is not dangerous, but it can grow, causing bleeding, making intercourse difficult and identifying difficulties with conception and childbirth.

Complications

Also, postponing the moment of surgery can lead to serious complications – common inflammatory processes, severe bleeding and mucosal atrophy, which may subsequently become the reason for the need to remove the uterus.

Advantages of the operation with us

Although cervical polypectomy surgery is considered safe and relatively easy to perform, it is important to find a medical center whose doctors can be trusted with their reproductive health.”Operating room number 1″ clinic “Paracelsus” in the city of Aleksandrov is a multidisciplinary surgery center that provides quality medical care. Comfortable conditions for patients, powerful high-tech equipment, an emphasis on minimally invasive interventions and a team of experts in all areas of surgery – these and other advantages distinguish our institution. Sign up to us by phone or online.

Removal of polyps (polypectomy) of the uterine cavity and cervix in Samara

Removal of polyps on the cervix and in the uterine cavity itself is a fairly common procedure.A polyp is a pathological proliferation of mucous membranes in a separate area. This can become a serious obstacle to a possible pregnancy and cause discomfort in everyday life.

Cost of services …

Small polyps usually don’t cause any problems. Many patients before the examination did not even know about their existence. They can be small and disappear. for example, if their growth was caused by hormonal imbalance, which was corrected by treatment.

However, if the polyp is large or troublesome (pain, discharge, irregularities in cycles), it should be removed. We also recommend a preventive examination and polypectomy in preparation for pregnancy.

Preparation for the procedure

Preparation for the removal of uterine polyps is simple and is needed to reduce all possible risks.

After consultation and examination, the doctor may prescribe additional tests and diagnostics. for example:

general blood test;
blood clotting test;
Ultrasound OMT;
cytological analysis of scrapings from the cervical canal and uterus.

It is recommended to refuse food intake 12 hours before the start of polypectomy.

How is polyp removal performed

In the “CLINIC OF FIVE BLAGS” in Samara, polypectomy is performed by the most modern and reliable method – radio wave surgery.

It has a number of undeniable advantages:

low injury rate;
does not affect fertility;
without bleeding;
great accuracy and the ability to very thoroughly remove the damaged area.

If you have already found a polyp, make an appointment and consultation with a gynecologist at our clinic. An experienced doctor will examine and analyze your situation individually. He can order additional tests and give recommendations. In some cases, it is necessary to remove polyps, but sometimes therapy and observation can be dispensed with (if the polyp is small and does not grow further).

REMOVING POLYPS / Services / Medical and Diagnostic Center MedExpert Saratov / Engels

Rectal polyps are benign formations that are outgrowths on the intestinal mucosa.There is a possibility of their degeneration into malignant tumors.

Polyps of the rectum (anal canal) do not respond to conservative treatment, therefore, if such polyps are found (even if they do not cause the patient any discomfort), they must be removed.

In the Department of Proctology of the Medical Center Medexpert, the removal of polyps of the anal canal and rectum is carried out by the method of radio wave surgery using the Surgitron apparatus.

HOW DOES THE POLYPS BE DELETED?

The doctor uses the electrode of the apparatus instead of a scalpel and the separation of the tissue of the formation is carried out not with the help of mechanical action, but thanks to the directed flux of high-frequency radio waves.The technique is highly effective and safe, therefore it can be used in patients of any age.

WHAT ARE THE ADVANTAGES OF POLYPS REMOVAL BY RADIO WAVE METHOD?

This method of performing the operation has its advantages:

Almost complete absence of pain;
Safety – burns when using a radio electrode are excluded;
Short recovery period, the patient returns to normal life as quickly as possible, no scars remain after the procedure;
No hospital stay or general anesthesia is required;
Blood loss is minimized;
Low risk of complications in the postoperative period – wounds on the mucous membrane rarely become infected and heal quickly.
Absence of relapses of the disease.

Radio wave removal of rectal polyps is a minimally invasive technique and is easily tolerated by patients, therefore it is a good alternative to other methods of treatment.

There are contraindications for this procedure, therefore, a specialist consultation is required.

In our center, removal of rectal polyps is performed by a coloproctologist, oncologist, Candidate of Medical Sciences OLGA VLADIMIROVNA KOCHENKOVA.

Appointment

Ask a Question

Doctor’s Schedule

Price list for the services of the Center “Institute of Health”

ALLERGOLOGY (cationic protein)
Eosinophilic cationic protein	1600
DETERMINATION OF SPECIFIC IgE
Screening for inhaled allergens
Screening for household allergens – house dust (D.Pteronyssimus, D.farinae, cockroach)	1150
Screening for bed feather allergens (goose feather, duck feather)	1150
Screening for allergens of microscopic fungi (aspergillus fumigatus, alterna-ria tenuis, cladosporium herba-rum, penicillium notatum)	1150
Screening for bird feather mixture allergens (budgerigar, canary, parakeet, finch)	1700
Screening of grass allergens No. 1 (hedgehog, meadow fescue, chaff, timothy grass, meadow bluegrass)	1700
Screening of grass allergens No. 2 (finger pig, chaff, timothy grass, meadow bluegrass, noticeable buckwheat, sorghum)	1700
Screening of grass allergens No. 3 (sweet spikelet, chaff, timothy grass, sowing rye, woolly bukharnik)	1700
Screening of grass allergens No. 4 (sweet spikelet, chaff, common reed, rye, woolly bukharnik)	1700
Screening of grass allergens No. 6 (finger pig, chaff, sorghum, bonfire, woolly bukharnik, noticeable buckwheat)	1700
Screening for plant allergens (ragweed, wormwood, dandelion, dandelion, goldenrod)	1700
Screening for allergens of early flowering trees (gray alder, hazel, elm, willow, poplar)	1700
Screening for allergens of late flowering trees (ash-leaved maple, warty birch, oak, beech, walnut)	1700
Screening for food allergens
Fruit (banana, orange, apple, peach)	1150
Balanced mixture of inhaled and food allergens for screening atopy for children over 4 years of age and adults.	1900
Balanced mixture of inhaled and food allergens for screening atopy for children under 4 years old	2500
Nuts (peanuts, American walnuts, hazelnuts, almonds, coconut)	1900
Fish (cod, shrimp, blue mussel, tuna, salmon)	1900
Vegetables (tomato, spinach, cabbage, red pepper)	1900
Meat (pork, beef, chicken, turkey)	1900
Screening of grain allergens (wheat, rye, barley, rice)	1900
Children’s food panel # 1 (egg white, cow’s milk, wheat, cod, peanuts, soybeans)	1900
Children’s food panel No. 2 (cod, wheat, soybeans, hazelnuts)	1900
Animal allergens
Epithelium and feline dander	650
Dog hair	650
Canine epithelium	650
Canary plumage	650
Parrot plumage	650
Hamster epithelium	650
Camel wool	650
Cockroach (red)	650
Guinea pig	650
Bloodworms (larva of a dergun mosquito)	650
Daphnia (water flea)	650
Mol	650
Domestic bee venom	650
Wasp venom	650
Hornet venom	650
Horse dandruff	1300
Chinchilla epithelium	1300
Food allergens
Egg white	650
Egg yolk	650
Cow’s milk	650
Goat’s milk	650
Swiss cheese	650
Blue cheese	650
Cheeder	650
Edam cheese	650
Wheat	650
Rye	650
Oats	650
Gluten	650
Soybean	650
Peanuts	650
Hazelnuts	650
Walnut	650
Almond	650
Cod	650
Crabs	650
Shrimp	650
Blue Mussel	650
Tuna	650
Salmon	650
Pork	650
Beef	650
Lamb	650
Turkey	650
Duck	650
Goose	650
Chicken	650
Spinach	650
Celery	650
Zucchini	650
Bell pepper	650
Carrot	650
Potatoes	650
Tomatoes	650
Orange	650
Mandarin	650
Pineapple	650
Kiwi	650
Strawberry (wild strawberry)	650
Apple	650
Peach	650
Banana	650
Chocolate (cocoa)	650
Honey	650
190 food allergens	43300
88 food allergens	25050
Boiled milk (cow)	1200
Rice	1200
Buckwheat	1200
Corn	1200
Peas	1200
Hake	1200
Pacific squid	1200
Parsley	1200
Pumpkin	1200
Avocado	1200
Grapefruit	1200
Lemon	1200
Melon	1200
Pear	1200
Sugar beet	1200
Poppy	1200
Vanilla	1200
Coffee beans	1200
Tea leaves	1200
Occupational allergens
Latex	1200
Formaldehyde / formalin	1200
Drug allergens
Penicillin G	1300
Penicillin V	1300
Amoxicillin	1300
Microscopic examination for eosinophils (nasal swab, conjunctival swab)	370
DETERMINATION OF SPECIFIC IgG
90 food allergens (IgG total)	14800
190 food allergens (IgG4)	48000
88 food allergens (IgG4)	25000
DETERMINATION OF SPECIFIC IgE
Drug allergens
Articaine \ ultracaine (ubistezine, septanest)	1050
Mepivacaine / Polocaine (Scandonest, Scandinibsa, Mepivastezine)	1050
Articaine / ultracaine + epinephrine (adrenaline) (alfacaine, artifrinum, brilocaine-adrenaline, primacaine with adrenaline, ubistezine forte, septanest with adrenaline, cytocartin)	1750
Mepivacaine / polacaine + epinephrine (adrenaline) (Scandinibsa forte)	1750
Lidocaine (Xylocaine, Versatis, Helicaine, Dinexan, Lycaine, Luan), blood / serum	720
Procaine (Novocaine, Novocaine bufus, Novocaine-Vmal), blood / serum	720
Identification of allergic components of plant pollen.Ig E, ImmunoCAP (Phadia AB)
t215, Warty birch (Betula verrucosa), rBet v 1 (recombinant, major), Ig E, ImmunoCAP® (Phadia AB)	2300
t221, Warty birch (Betula verrucosa), rBet v 2, rBet v 4 (recombinant, minor), Ig E, ImmunoCAP® (Phadia AB)	2300
w230, Ambrosia elatior, nAmb a 1 (native, major), Ig E, ImmunoCAP® (Phadia AB)	2300
w231, Common wormwood (Artemisia vulgaris), nArt v 1 (native, major), Ig E, ImmunoCAP® (Phadia AB)	2300
w233, Common wormwood (Artemisia vulgaris), nArt v 3 (native, major), Ig E, ImmunoCAP® (Phadia AB)	2300
g213, Timothy grass (Phleum pratense), rPhl p1, rPhl p5b (recombinant, major), Ig E, ImmunoCAP® (Phadia AB)	2300
g214, Timothy grass (Phleum pratense), rPhl p7, rPhl p12 (recombinant, minor), Ig E, ImmunoCAP® (Phadia AB)	2300
Identification of animal allergic components.Ig E, ImmunoCAP® (Phadia AB)
e94, Cat (Felis domesticus), rFel d 1 (recombinant, major), Ig E, ImmunoCAP® (Phadia AB)	2300
e220, Feline, serum albumin (Felis domesticus), nFel d2 (native), Ig E, ImmunoCAP® (Phadia AB)	2300
e101, Dog (Canis familiaris), rCan f 1 (recombinant, major), Ig E, ImmunoCAP® (Phadia AB)	2300
e102, Dog (Canis familiaris), rCan f 2 (recombinant, minor), Ig E, ImmunoCAP® (Phadia AB)	2300
e221, Dog, serum albumin (Canis familiaris), nCan f 3 (native), Ig E, ImmunoCAP® (Phadia AB)	2300
Identification of household allergy components.Ig E, ImmunoCAP® (Phadia AB).
m229, Alternaria alternata, rAlt a 1 (recombinant, major), Ig E, ImmunoCAP® (Phadia AB)	2300
Identification of allergic components of food allergens. Ig E, ImmunoCAP® (Phadia AB).
f422, Peanut (Arachis hypogaea), rAra h 1 (recombinant, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
f423, Peanut (Arachis hypogaea), rAra h 2 (recombinant, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
f424, Peanut (Arachis hypogaea), rAra h 3 (recombinant, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
f427, Peanut (Arachis hypogaea), rAra h 9, (recombinant, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
f416, Wheat, omega-5 Gliadin (Triticum spp.), rTri a 19 (recombinant, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
f353, Soy (Glycine max), rGly m 4 (recombinant, heat-labile), Ig E, ImmunoCAP® (Phadia AB)	2300
f233, Egg, ovomucoid (Gallus spp.), NGal d 1 (native, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
f232, Egg, ovalbumin (Gallus spp.), NGal d 2 (native, heat-labile), Ig E, ImmunoCAP® (Phadia AB)	2300
f323, Egg, conalbumin (Gallus spp.), nGal d3 (native, heat-labile), Ig E, ImmunoCAP® (Phadia AB)	2300
k208, Egg, lysozyme (Gallus spp.), NGal d4 (native), Ig E, ImmunoCAP® (Phadia AB)	2300
f355, Common carp (Cyprinus carpio), rCyp c 1 (recombinant, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
f78, Cow’s milk, casein (Bos spp.) NBos d 8 (native, thermostable), Ig E, ImmunoCAP® (Phadia AB)	2300
DIAGNOSTICS OF ALLERGIES using ImmunoCAP® technology (Phadia AB, Thermo Fisher Scientific, Sweden)
Immunoglobulin E total (Total Ig E), ImmunoCAP® (Phadia AB)	600
Eosinophilic Cationic Protein (ECP), ImmunoCAP® (Phadia AB)	1300
Tryptase	2600
ALLERGY DIAGNOSTICS, SURVEY PROGRAMS, ImmunoCAP® (Phadia AB)
Eczema.Ig E, ImmunoCAP® (Phadia AB) (e1, Cat, dandruff, Ig E; e5, Dog, dandruff, Ig E; d1, Dermatophagoides pteronyssinus, Ig E; f1, Egg white, Ig E; f2, Cow’s milk, Ig E; f24, Shrimps, Ig E; f3, Atlantic cod, Ig E; f13, Peanuts, Ig E; f4, Wheat, Ig E; f14, Soy, Ig E; f17, Hazelnuts, Ig E)	7200
Asthma / Rhinitis Adult. Ig E, ImmunoCAP® (Phadia AB) (g6, Meadow timothy, Ig E; w1, High ragweed, Ig E; w6, Common wormwood, Ig E; t3, Warty birch, Ig E; t25, High ash, Ig E; e1, Cat, dandruff, Ig E; e5, Dog, dandruff, Ig E; d1, Dermatophagoides pteronyssinus, Ig E; i6, Red cockroach, Ig E; m6, Alternaria alternata, Ig E)	6500
Wheeze / Rhinitis Child.Ig E, ImmunoCAP® (Phadia AB) g6, Timothy grass, Ig E; w6, Common wormwood, Ig E; t3, Warty birch, Ig E; t25, Ash high, Ig E; e1, Cat, dandruff, Ig E; e5, Dog, dandruff, Ig E; d1, Dermatophagoides pteronyssinus, Ig E; f1, Egg white, Ig E; f2, Cow’s milk, Ig E; f13, Peanuts, Ig E)	6500
Prediction of the risk of vaccination. ImmunoCAP® (Phadia AB) (Tryptase; f232, Ovalbumin, nGal d 2 (heat-labile), Ig E; f45, Baker’s yeast, Ig E; k80, Formaldehyde / formalin, Ig E)	5400
Prediction of the risk of surgical intervention.ImmunoCAP® (Phadia AB) (Tryptase; c74, Gelatin, Ig E; c8, Chlorhexidine, Ig E; k82, Latex, Ig E)	4350
Screening of plant pollen allergens. Ig E, ImmunoCAP® (Phadia AB).
gx1, Grain pollen: hedgehog (g3, Dactylis glomerata), meadow fescue (g4, Festuca elatior), perennial chaff (g5, Lolium perenne), meadow timothy (g6, Phleum pratense), bluegrass Poa pratensis). Ig E, ImmunoCAP® (Phadia AB)	950
gx3, Grain pollen: fragrant spikelet (g1, Anthoxanthum odoratum), perennial rye grass (g5, Lolium perenne), meadow timothy (g6, Phleum pratense), sowing rye (g12, Secale gereale), bukhara Holcus lanatus).Ig E, ImmunoCAP® (Phadia AB)	950
gx4, Grain pollen: sweet spikelet (g1, Anthoxanthum odoratum), perennial chaff (g5, Lolium perenne), common reed (g7, Phragmites communis), sowing rye (g12, Secale cereale), g13 wool Holcus lanatus). Ig E, ImmunoCAP® (Phadia AB)	950
gx6, Grain pollen: finger pork (g2, Cynodon dactylon), perennial chaff (g5, Lolium perenne), Aleppo sorghum (g10, Sorghum halepense), awnless bonfire (g11, Bromopsis g13ermis, woolly Holcus lanatus), swept buckwheat (g17, Paspalum notatum).Ig E, ImmunoCAP® (Phadia AB)	950
wx5, Weed pollen: high ragweed (w1, Ambrosia elatior), common wormwood (w6, Artemisia vulgaris), common daisy (w7, Chrysanthemum leucanthemum), medicinal dandelion (w8, Taraxacum, vulgare), Solidago virgaurea). Ig E, ImmunoCAP® (Phadia AB)	950
tx5, Tree pollen: gray alder (t2, Alnus incana), common hazel (t4, Corylus avellana), thick-leaved elm (t8, Ulmus americana), goat willow (t12, Salix caprea), deltoid poplar (t14, Populus deltoides).Ig E, ImmunoCAP® (Phadia AB)	950
tx6, Tree pollen: ash-leaved maple (t1, Acer negundo) warty birch (t3, Betula verrucosa), large-leaved beech (t5, Fagus grandifolia), white oak (t7, Quercus alba), walnut (t10, Juglans ). Ig E, ImmunoCAP® (Phadia AB)	950
Screening for animal allergens and house dust. Ig E, ImmunoCAP® (Phadia AB).
ex72, Bird feathers: budgerigar (e78, Melopsittacus undulatus), domestic canary (e201, Serinus canarius), long-tailed parrot (e196), parrot (e213, Ara spp.), finches (e214, Lonchura domestrica). Ig E, ImmunoCAP (Phadia AB)	950
hx2, Household dust: Hollister-Stier Labs. (h3), house dust mite (d1, Dermatophagoides pteronyssinus), house dust mite (d2, Dermatophagoides farinae), red cockroach (i6, Blatella germanica). Ig E, ImmunoCAP (Phadia AB)	950
ex71, Bed feather: goose (e70, Anser anser), chicken (e85, Gallus domesticus), ducks (e86, Anas platyrhynca), turkey (e 89, Meleagris gallopavo).Ig E, ImmunoCAP (Phadia AB)	950
mx1, Microscopic fungi: Penicillium notatum (m1), Cladosporium herbarum (m2), Aspergillus fumigatus (m3), Alternaria alternata (m6). Ig E, ImmunoCAP® (Phadia AB)	950
mx2, Microscopic fungi: Penicillium notatum (m1), Cladosporium herbarum (m2), Aspergillus fumigatus (m3), Alternaria alternata (m6), Helminthosporium halodes (Setomelanomma rostrata) (m8).Ig E, ImmunoCAP® (Phadia AB)	950
Screening for food allergens
fx5, Children’s food panel No. 1: egg white (f1, Gallus spp.), Cow’s milk (f2, Bos spp.), Atlantic cod (f3, Gadus morhua), wheat (f4, Triticum aestivum), peanuts ( f13, Arachis hypogaea), soy (f14, Glycine max). Ig E, ImmunoCAP® (Phadia AB)	950
fx27, Children’s food panel No. 2: Atlantic cod (f3, Gadus morhua), wheat (f4, Triticum aestivum), soybeans (f14, Glycine max), hazelnuts (f17, Corylus avellana).Ig E, ImmunoCAP® (Phadia AB)	1200
fx20, Cereals: wheat (f4, Triticum aestivum), rye (f5, Secale cereale), barley (f6, Hordeum vulgare), rice (f9, Oryza sativa). Ig E, ImmunoCAP® (Phadia AB)	950
fx1, Nuts: peanuts (f13, Arachis hypogaea), hazelnuts (f17, Corylus avellana), American walnut (f18, Bertholletia excelsa), almonds (f20, Amygdalus communis), coconut (f36, Cocos nucifera. Ig E, ImmunoCAP® (Phadia AB)	950
fx2, Fish and seafood: Atlantic cod (f3, Gadus morhua), shrimp (f24, Pandalus borealis, Penaeus monodon, Metapenaeopsis barbata, Metapenaus joyneri), blue tuna mussel (f37, Mytilus edulis), Thunder albacares), Atlantic salmon (salmon) (f41, Salmo salar).Ig E, ImmunoCAP® (Phadia AB)	950
fx15, Fruits: orange (f33, Citrus sinensis), apple (f49, Malus x domestica), banana (f92, Musa acuminata / sapientum / paradisiaca), peach (f95, Prunus persica). Ig E, ImmunoCAP® (Phadia AB)	950
Identification of grass pollen allergens. Ig E, ImmunoCAP® (Phadia AB)
g13, Woolly Bukhark (Holcus lanatus), Ig E, ImmunoCAP® (Phadia AB)	800
g17, Buckwheat (Paspalum notatum), Ig E, ImmunoCAP® (Phadia AB)	800
g3, Hedgehog (Dactylis glomerata), Ig E, ImmunoCAP® (Phadia AB)	800
g1, Sweet spikelet (Anthoxanthum odoratum), Ig E, ImmunoCAP® (Phadia AB)	800
g11, Awnless bonfire (Bromopsis inermis), Ig E, ImmunoCAP® (Phadia AB)	800
g202, Common corn (Zea mays), Ig E, ImmunoCAP® (Phadia AB)	800
g16, Meadow foxtail (Alopecurus pratensis), Ig E, ImmunoCAP® (Phadia AB)	800
g8, Poa pratensis, Ig E, ImmunoCAP® (Phadia AB)	800
g14, Sowing oats (Avena sativa), Ig E, ImmunoCAP® (Phadia AB)	800
g4, Meadow fescue (Festuca pratensis), Ig E, ImmunoCAP® (Phadia AB)	800
g5, Perennial chaff (Lolium perenne), Ig E, ImmunoCAP® (Phadia AB)	800
g9, Red bent (Agrostis stolonifera), Ig E, ImmunoCAP® (Phadia AB)	800
g15, Sowing wheat (Triticum sativum), Ig E, ImmunoCAP® (Phadia AB)	800
g12, Rye (Secale cereale), Ig E, ImmunoCAP® (Phadia AB)	800
g2, Pig finger (Cynodon dactylon), Ig E, ImmunoCAP® (Phadia AB)	800
g10, Aleppo Sorghum (Sorghum halepense), Ig E, ImmunoCAP® (Phadia AB)	800
g6, Timothy grass (Phleum pratense), Ig E, ImmunoCAP® (Phadia AB)	800
g7, Common reed (Phragmites communis), Ig E, ImmunoCAP® (Phadia AB)	800
g201, Common barley (Hordeum vulgare), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of weed pollen allergens.Ig E, ImmunoCAP® (Phadia AB).
w82, Amaranth (Palmer’s Schiritsa) (Amaranthus palmeri), Ig E, ImmunoCAP® (Phadia AB)	800
w1, Ambrosia elatior, Ig E, ImmunoCAP® (Phadia AB)	800
w12, Goldenrod (Solidago virgaurea), Ig E, ImmunoCAP® (Phadia AB)	800
w15, Atriplex lentiformis, Ig E, ImmunoCAP® (Phadia AB)	800
w10, White Mary (Chenopodium album), Ig E, ImmunoCAP® (Phadia AB)	800
w7, Common Lemongrass (Chrysanthemum leucanthemum), Ig E, ImmunoCAP® (Phadia AB)	800
w8, Dandelion (Taraxacum vulgare), Ig E, ImmunoCAP® (Phadia AB)	800
w9, Plantago lanceolata, Ig E, ImmunoCAP® (Phadia AB)	800
w204, Common sunflower (Helianthus annuus), Ig E, ImmunoCAP® (Phadia AB)	800
w6, Artemisia vulgaris, Ig E, ImmunoCAP® (Phadia AB)	800
w5, Wormwood (Artemisia absinthium), Ig E, ImmunoCAP® (Phadia AB)	800
w206, Chamomile (Matricaria chamomilla), Ig E, ImmunoCAP® (Phadia AB)	800
w23, Horse sorrel (Rumex crispus), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of tree pollen allergens.Ig E, ImmunoCAP® (Phadia AB).
t19, Acacia longifolia, Ig E, ImmunoCAP® (Phadia AB)	800
t3, Warty birch (Betula verrucosa), Ig E, ImmunoCAP® (Phadia AB)	800
t205, Black elder (Sambucus nigra), Ig E, ImmunoCAP® (Phadia AB)	800
t5, Large-leaved beech (Fagus grandifolia), Ig E, ImmunoCAP® (Phadia AB)	800
t8, American Elm (Ulmus americana), Ig E, ImmunoCAP® (Phadia AB)	800
t45, Thick-leaved elm (Ulmus crassifolia), Ig E, ImmunoCAP® (Phadia AB)	800
t7, White Oak (Quercus alba), Ig E, ImmunoCAP® (Phadia AB)	800
t201, Norway spruce (Picea excelsa), Ig E, ImmunoCAP® (Phadia AB)	800
t12, Goat Willow (Salix caprea), Ig E, ImmunoCAP® (Phadia AB)	800
t203, Horse chestnut (Aesculus hippocastanum), Ig E, ImmunoCAP® (Phadia AB)	800
t1, Ash-leaved maple (Acer negundo), Ig E, ImmunoCAP® (Phadia AB)	800
t4, Common hazel (Corylus avellana), Ig E, ImmunoCAP® (Phadia AB)	800
t208, Small-leaved linden (Tilia cordata), Ig E, ImmunoCAP® (Phadia AB)	800
t57, Juniperus virginiana, Ig E, ImmunoCAP® (Phadia AB)	800
t2, Gray alder (Alnus incana), Ig E, ImmunoCAP® (Phadia AB)	800
t11, Platanus acerifolia, Ig E, ImmunoCAP® (Phadia AB)	800
t55, Paniculata Broom (Cytisus scoparius), Ig E, ImmunoCAP® (Phadia AB)	800
t14, Populus deltoides, Ig E, ImmunoCAP® (Phadia AB)	800
t70, White mulberry (Morus alba), Ig E, ImmunoCAP® (Phadia AB)	800
t15, American Ash (Fraxinus americana), Ig E, ImmunoCAP® (Phadia AB)	800
t25, High Ash (Fraxinus excelsior), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of animal allergens.Ig E, ImmunoCAP® (Phadia AB)
e201, Domestic canary (Serinus canarius), plumage, Ig E, ImmunoCAP® (Phadia AB)	800
e1, Cat (Felis domesticus), dandruff, Ig E, ImmunoCAP® (Phadia AB)	800
e3, Horse (Equus caballus), Dandruff, Ig E, ImmunoCAP® (Phadia AB)	800
e6, Guinea pig (Cavia porcellus), epithelium, Ig E, ImmunoCAP® (Phadia AB)	800
e213, Parrot (Ara spp.), plumage, Ig E, ImmunoCAP® (Phadia AB)	800
e5, Dog (Canis familiaris), dandruff, Ig E, ImmunoCAP® (Phadia AB)	800
e84, Hamster (family Cricetidae), epithelium, Ig E, ImmunoCAP® (Phadia AB)	800
e208, Chinchilla laniger, epithelium, Ig E, ImmunoCAP® (Phadia AB)	800
Identification of house dust mite allergens.Ig E, ImmunoCAP® (Phadia AB)
d2, House dust mite (Dermatophagoides farinae), Ig E, ImmunoCAP® (Phadia AB)	800
d1, House dust mite (Dermatophagoides pteronyssinus), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of insect allergens. Ig E, ImmunoCAP® (Phadia AB)
i8, Mole (Bombyx mori), Ig E, ImmunoCAP® (Phadia AB)	800
i73, Bloodworms (Chironomus thummi), Ig E, ImmunoCAP® (Phadia AB)	800
i6, Red cockroach (Blatella germanica), Ig E, ImmunoCAP® (Phadia AB)	800
i3, Wasp venom (Vespula spp.), Ig E, ImmunoCAP® (Phadia AB)	800
i4, Paper Wasp Venom (Polistes spp.), Ig E, ImmunoCAP® (Phadia AB)	800
i1, Honey Bee Venom (Apis mellifera), Ig E, ImmunoCAP® (Phadia AB)	800
i75, Hornet Venom (Vespa crabro), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of allergens of microscopic fungi.Ig E, ImmunoCAP® (Phadia AB)
m6, Alternaria alternata, Ig E, ImmunoCAP® (Phadia AB)	800
m3, Aspergillus fumigatus, Ig E, ImmunoCAP® (Phadia AB)	800
m207, Aspergillus niger, Ig E, ImmunoCAP® (Phadia AB)	800
m7, Botrytis cinerea, Ig E, ImmunoCAP® (Phadia AB)	800
m2, Cladosporium herbarum, Ig E, ImmunoCAP® (Phadia AB)	800
m4, Mucor racemosus, Ig E, ImmunoCAP® (Phadia AB)	800
m1, Penicillium notatum, Ig E, ImmunoCAP® (Phadia AB)	800
Identification of helminth allergens.Ig E, ImmunoCAP® (Phadia AB).
p4, Anisakis spp., Ig E, ImmunoCAP® (Phadia AB)	800
p1, Human Ascaris (Ascaris lumbricoides), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of food allergens. Meat and egg. Ig E, ImmunoCAP® (Phadia AB).
f88, Lamb (Ovis spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f27, Beef (Bos spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f284, Turkey (Meleagris gallopavo), Ig E, ImmunoCAP® (Phadia AB)	800
f83, Chicken (Gallus spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f26, Pork (Sus spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f1, Egg White (Gallus spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f75, Egg yolk (Gallus spp.), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of food allergens. Dairy products. Ig E, ImmunoCAP® (Phadia AB)
f2, Cow’s milk (Bos spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f231, Boiled cow’s milk (Bos spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f300, Goat milk, Ig E, ImmunoCAP® (Phadia AB)	800
f82, Blue cheese, Ig E, ImmunoCAP® (Phadia AB)	800
f81, Cheddar Cheese, Ig E, ImmunoCAP® (Phadia AB)	800
Identification of food allergens.Fish and seafood. Ig E, ImmunoCAP® (Phadia AB)
f258, Squid (family Loliginidae), Ig E, ImmunoCAP® (Phadia AB)	800
f23, Crab (Chionocetes spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f24, Shrimps (family Pandalus, Penaeidae), Ig E, ImmunoCAP® (Phadia AB)	800
f41, Atlantic salmon (salmon) (Salmo salar), Ig E, ImmunoCAP® (Phadia AB)	800
f37, Blue mussel (Mytilus edulis), Ig E, ImmunoCAP® (Phadia AB)	800
f3, Atlantic cod (Gadus morhua), Ig E, ImmunoCAP® (Phadia AB)	800
f40, Yellowfin tuna (Thunnus albacares), Ig E, ImmunoCAP® (Phadia AB)	800
f204, Rainbow Trout (Oncorhynchus mykiss), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of food allergens.Seeds, legumes and nuts. Ig E, ImmunoCAP® (Phadia AB)
f18, American walnut (Bertholletia excelsa), Ig E, ImmunoCAP® (Phadia AB)	800
f13, Peanut (Arachis hypogaea), Ig E, ImmunoCAP® (Phadia AB)	800
f79, Gluten (Common), Ig E, ImmunoCAP® (Phadia AB)	800
f12, Peas (Pisum sativum), Ig E, ImmunoCAP® (Phadia AB)	800
f256, Walnut (Juglans spp.), Ig E, ImmunoCAP® (Phadia AB)	1600
f11, Buckwheat (buckwheat) (Fagopyrum esculentum), Ig E, ImmunoCAP® (Phadia AB)	800
f36, Coconut (Cocos nucifera), Ig E, ImmunoCAP® (Phadia AB)	800
f8, Corn (Zea mays), Ig E, ImmunoCAP® (Phadia AB)	800
f333, Linseed (Linum usitatissimum), Ig E, ImmunoCAP® (Phadia AB)	800
f224, Poppy seed (Papaver somniferum), Ig E, ImmunoCAP® (Phadia AB)	800
f20, Almond (Amygdalus communis), Ig E, ImmunoCAP® (Phadia AB)	800
f7, Oats (Avena sativa), Ig E, ImmunoCAP® (Phadia AB)	800
f202, Cashew Nut (Anacardium occidentale), Ig E, ImmunoCAP® (Phadia AB)	800
f4, Wheat (Triticum aestivum), Ig E, ImmunoCAP® (Phadia AB)	800
f9, Rice (Oryza sativa), Ig E, ImmunoCAP® (Phadia AB)	800
f5, Rye (Secale cereale), Ig E, ImmunoCAP® (Phadia AB)	800
f14, Soy (Glycine max), Ig E, ImmunoCAP® (Phadia AB)	800
f203, Pistachios (Pistacia vera), Ig E, ImmunoCAP® (Phadia AB)	800
f17, Hazelnut (Corylus avellana), Ig E, ImmunoCAP® (Phadia AB)	800
f6, Barley (Hordeum vulgare), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of food allergens.Vegetables. Ig E, ImmunoCAP® (Phadia AB).
f216, Cabbage (Brassica oleracea var.capitata), Ig E, ImmunoCAP® (Phadia AB)	800
f35, Potato (Solanum tuberosum), Ig E, ImmunoCAP® (Phadia AB)	800
f48, Onion (Allium cepa), Ig E, ImmunoCAP® (Phadia AB)	800
f31, Carrot (Daucus carota), Ig E, ImmunoCAP® (Phadia AB)	800
f218, Sweet pepper (paprika) (Capsicum annuum), Ig E, ImmunoCAP® (Phadia AB)	800
f227, Sugar beet (Beta vulgaris), Ig E, ImmunoCAP® (Phadia AB)	800
f85, Celery (Apium graveolens), Ig E, ImmunoCAP® (Phadia AB)	800
f25, Tomato (Lycopersicon esculetum), Ig E, ImmunoCAP® (Phadia AB)	800
f225, Pumpkin (Cucurbita pepo), Ig E, ImmunoCAP® (Phadia AB)	800
f47, Garlic (Allium sativum), Ig E, ImmunoCAP® (Phadia AB)	800
f214, Spinach (Spinachia oleracea), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of food allergens.Fruits, berries. Ig E, ImmunoCAP® (Phadia AB)
f96, Avocado (Persea americana), Ig E, ImmunoCAP® (Phadia AB)	800
f210, Pineapple (Ananas comosus), Ig E, ImmunoCAP® (Phadia AB)	800
f33, Orange (Citrus sinensis), Ig E, ImmunoCAP® (Phadia AB)	800
f92, Banana (Musa acuminata / sapientum / paradisiaca), Ig E, ImmunoCAP® (Phadia AB)	800
f209, Grapefruit (Citrus paradisi), Ig E, ImmunoCAP® (Phadia AB)	800
f94, Pear (Pyrus communis), Ig E, ImmunoCAP® (Phadia AB)	800
f87, Melon (Cucumis melo spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f84, Kiwi (Actinidia deliciosa), Ig E, ImmunoCAP® (Phadia AB)	800
f44, Strawberry (Fragaria vesca), Ig E, ImmunoCAP® (Phadia AB)	800
f208, Lemon (Citrus limon), Ig E, ImmunoCAP® (Phadia AB)	800
f302, Mandarin (Citrus reticulata), Ig E, ImmunoCAP® (Phadia AB)	800
f294, Passiflora edulis, Ig E, ImmunoCAP® (Phadia AB)	800
f293, Papaya (Carica papaya), Ig E, ImmunoCAP® (Phadia AB)	800
f95, Peach (Prunus persica), Ig E, ImmunoCAP® (Phadia AB)	800
f49, Apple (Malus x domestica), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of food allergens.Miscellaneous. Ig E, ImmunoCAP® (Phadia AB)
f234, Vanilla (Vanilla planifolia), Ig E, ImmunoCAP® (Phadia AB)	800
f45, Baker’s Yeast (Saccharomyces cerevisiae), Ig E, ImmunoCAP® (Phadia AB)	800
f93, Cocoa (Theobroma cacao), Ig E, ImmunoCAP® (Phadia AB)	800
f221, Coffee (Coffea spp.), Ig E, ImmunoCAP® (Phadia AB)	800
f247, Honey, Ig E, ImmunoCAP® (Phadia AB)	800
f86, Parsley (Petroselinum crispum), Ig E, ImmunoCAP® (Phadia AB)	800
f222, Tea (Theaceae), Ig E, ImmunoCAP® (Phadia AB)	800
Identification of drug allergens.Ig E, ImmunoCAP® (Phadia AB)
c6, Amoxicilloyl, Ig E, ImmunoCAP® (Phadia AB)	800
c74, Gelatin, Ig E, ImmunoCAP® (Phadia AB)	800
c1, Penicillin (Penicilloyl G), Ig E, ImmunoCAP® (Phadia AB)	800
c2, Penicillin V (Penicilloyl V), Ig E, ImmunoCAP® (Phadia AB)	800
c8, Chlorhexidine, Ig E, ImmunoCAP® (Phadia AB)	800
Identification of occupational allergens.Ig E, ImmunoCAP® (Phadia AB)
k82, Latex (Hevea brasiliensis), Ig E, ImmunoCAP® (Phadia AB)	800
k80, Formaldehyde / Formalin, Ig E, ImmunoCAP® (Phadia AB)	800

Removal of uterine polyps, treatment and diagnosis, treatment and diagnosis in Kazan – “Scandinavia” Kazan

Polyps in the uterus are benign neoplasms that are attached to the inner wall of the uterus with “legs” or a wide base.The size of a polyp is from a few millimeters to 3-4 centimeters. Polyps can invade the vagina through the cervical canal. Polyps are diagnosed in women of all ages, starting from 10-11 years old.

An endometrial polyp is not dangerous if it is a benign formation and their number is small. In such cases, they can dissolve on their own. However, atypical, or adenomatous, polyps have a high likelihood of developing into a malignant tumor.More often this disease occurs in women in adulthood.

Symptoms of polyps in the uterus

The presence of polyps can be indicated by irregularities in the cycle of menstruation and bleeding outside their period. Also indirect symptoms of polyps are bleeding after menopause, discomfort during sex, leucorrhoea and pain in the lower abdomen.

Symptoms are also typical for endometriosis, fibroids and other gynecological diseases, so it is important to diagnose the pathology in time and prescribe treatment.

Causes of polyps in the uterus

The formation of polyps in the uterus is associated with irregularities in the work of the ovaries – too much estrogen enters the bloodstream, which causes the endometrium to grow.

The causes of uterine polyps can be:

Hormonal disorders;
Erosion of the cervix;
Chronic infections;
Inflammatory processes;
Genetic pathologies;
Abortion, gynecological operations.

Also at risk are women suffering from obesity, hypertension and diabetes mellitus.

Polyps during pregnancy

Placental polyps, which have formed from the placenta after a frozen pregnancy, abortion or complicated labor, are accompanied by profuse bleeding.

Benign formations can provoke infections and inflammation, and the proliferation of polyps can lead to miscarriage.Any type of polyp reduces the likelihood of a fertilized egg fixing in the uterus.

Polyps are removed only after childbirth. But the polyps detected during pregnancy will not affect the condition of the fetus and the expectant mother with quality control over the patient’s condition.

Treatment of polyps in the uterus

Treatment is carried out in a hospital setting

If symptoms are present, the patient should consult a gynecologist. To accurately diagnose polyps and establish their causes, the doctor prescribes an ultrasound of the pelvic organs, coloscopy and an x-ray examination of the uterine cavity.Also, a woman needs to pass smears for flora, oncocytology and infections.

Scandinavia (Ava-Kazan) has its own laboratory, so all tests can be taken in one place, and their results will be ready in a few days. In addition, there is no need to make a separate appointment for an expert-level ultrasound scan – the gynecologist conducts an ultrasound examination right in the office at the first appointment.

To determine the number, size and location of polyps, the doctor performs hysteroscopy with diagnostic curettage, after which a small piece of the polyp is sent for histological examination.

If the polyps are several millimeters long and it turns out to be not a cancerous tumor, the patient is prescribed conservative treatment without surgery – medication or hormonal therapy. After normalization of hormonal levels and the production of estrogen, small polyps dry out and are excreted with menstruation. However, even in this case, the patient needs constant observation by a gynecologist and regular ultrasound. In other cases, the polyps are scraped out, their bases are cauterized by the radio wave method.With a large number of polyps, the entire uterus is removed.

Since polyps are more often formed without pronounced symptoms, constant observation by a gynecologist and preventive examinations once a year is important.

A consultation with a gynecologist “Scandinavia” (“Ava-Kazan”) lasts 45 minutes, a minimum examination during the initial admission to a multidisciplinary clinic allows detecting pathologies in the early stages, and a general smear for oncocytology is hardly the only way to recognize cancer in the initial stages.

90,000 Removal of a polyp in the stomach in St. Petersburg

A polyp is a benign neoplasm that grows from the epithelial tissue of the stomach. These formations can be presented in a single or plural number, have different localization and sizes. In some cases, this disease can transform into malignant tumors, so doctors usually recommend removing the polyp in the stomach.

Causes of the appearance of polyps in the stomach

Several of the most common factors that can lead to the formation of polyps can be noted:

inflammatory diseases of the stomach;

90,019 old age;

infection with Helicobacter pylori or other microorganisms;
hereditary predisposition;
long-term use of certain groups of drugs.

Therefore, those people who have a history of one or more of the provoking factors described above should pay maximum attention to their stomach and regularly visit a gastroenterologist.

Clinical picture

The reason for a visit to a specialist may be specific symptoms that indicate the appearance of polyps in the stomach. These symptoms include:

painful sensations in the stomach of varying severity;
poor digestion;
nausea and vomiting;

90,019 poor appetite;

bad breath.

Not always polyps can manifest themselves. Very often, formations can exist hidden, and they are discovered by chance during fibrogastroscopy.

How to remove polyps

As noted earlier, sometimes polyps can develop into stomach cancer, so they need to be removed. Some patients refuse surgery to remove a polyp of the stomach, citing the fact that the disease does not bother them in any way. In such cases, careful and regular monitoring of the dynamics of the process is necessary.As a result, the polyp will still have to be removed, so it is best to do it right away and not expose yourself to unnecessary risks.

Currently, several methods of removing gastric polyps remain relevant:

Endoscopic technique. It is a minimally invasive procedure and is performed without incisions. With the help of endoscopic equipment, which enters the stomach through the oral cavity, the doctor finds the polyp and removes it with an electrocoagulator or a loop. This method is simple and quick, does not require general anesthesia and rarely leads to the development of serious complications.However, it can be used to remove small and single polyps.
Laser removal. It is a kind of endoscopic method. In this case, the polyp is vaporized by a laser. The advantage of this method is the ability to accurately control the depth of exposure, high accuracy, no bleeding, and a short rehabilitation period. Again, laser removal is only used for single, small polyps.
Abdominal surgery. It is a complete surgical procedure performed under general anesthesia. The scope of the operation is determined individually and may include the removal of some part of the stomach or the entire organ as a whole. Such a radical method is used in cases where there is a suspicion of stomach cancer or multiple polyposis is noted. In modern surgery, preference is given to low-traumatic techniques, therefore, instead of abdominal surgery, which involves a large incision of the anterior abdominal wall, in some cases, laparoscopic removal of the polyp can be used.

After removal of a polyp in the stomach, relapses of the disease may occur, therefore it is necessary to periodically undergo examination by a gastroenterologist. In addition, after the treatment, the doctor will draw up an individual list of dietary and lifestyle recommendations, which must be strictly observed.